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Abstract
Objective Combination of transcriptomic and retrospective clinical data, to assess anti-Mullerian hormone (AMH) functionality
at a cumulus cell level and evaluate AMH potential as a suitable marker for IVF outcomes (oocytes retrieved, number of day 3
embryos, gestation outcomes).
Design Raw RNA-sequencing data of cumulus cells sourced from younger (n = 10) patient group (group A) (age 29 (1 year of
age), baseline FSH 7.4 (0.5mIU/ml), AMH 4.67 (1.56 ng/ml)) and older (n = 10) patient group (group B) (age 43 (± 0.55 years of
age), baseline FSH 8 (0.8 mIU/ml), AMH 1.07 (0.44 ng/ml)) were employed to derive transcriptomic differences among high vs.
low AMH groups. We collected retrospectively patient data from 80 infertile patients selected according to pre-specified
inclusion criteria.
Setting Publicly available raw RNA-sequencing data were retrieved from the SRA database of NCBI resource GEO Accession
(GSM21575/35-44; GEO Accession: GSM21575/45-55). Retrospective data were collected from referrals to the Institute of
Reproductive Medicine, Lito Hospital of Athens and the Institute of Life, Iaso Hospital of Athens, between the periods of
March 2015 and April 2018.
Intervention(s) A fixed human menopausal gonadotropin (hMG) antagonist protocol was used for all patients. All patients had
serum AMH levels measured within a 3-month period prior to stimulation and serum levels of FSH and estradiol (day 2 of
menstrual cycle; E2) (Clinical Trial code NV24042014).
Main outcome measure(s) The primary outcomes were identification of transcriptomic variations among high (group A) vs. low
(group B) AMH patients. Retrospective data primary outcomes were number of oocytes retrieved, fertilized successfully (grades
A and B, day 2 embryos), and total number of day 3 embryos. Secondary outcome was live birth rate. Finally, we compared
primary outcomes with AMH and FSH level as well as their genetic pathways (interacting genes) to demonstrate the predictive
accuracy.
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Results Essential players of the AMH signaling cascade, namely, SMAD1, SMAD4, SMAD5, ALK1, and LEF1, were signifi-
cantly upregulated in group A (n 10) transcriptome. This biological clue was further supported by retrospective clinical data (n 80
participants), where AMHwas positively correlated with both oocytes retrieved and fertilized as well as number of day 3 (grades
A and B) embryos from patients undergoing IVF, in a statistically significant manner. AMH was further positive trend of
association with successful pregnancy outcomes.
Conclusion Overall, this study offers new insight on AMH effects upon cumulus cells and new aspects on how AMH might
promote oocyte integrity and embryo viability at a biochemical level as well as add to the current body of evidence supporting
AMH clinical potential as a more sensitive marker of IVF outcomes in comparison with FSH, regarding numbers of oocytes
received and high-quality day 2 and day 3 embryos.
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Introduction
Infertility presents a complex disorder with a vast range of
implications spanning from medical and psychological to so-
cioeconomic consequences, affecting 20–80 million people
across the world. While advancing age, health status, and life-
style factors present considerable causes of female infertility,
unexplained infertility is estimated to affect approximately
15% of couples [1]. A multitude of research has been dedicat-
ed to identifying the most reliable ovarian reserve markers to
predict the outcome of ovarian stimulation (OS), as it repre-
sents a critical cornerstone of assisted reproductive technolo-
gies (ART).]
The new classification criteria of infertile women, accord-
ing to their ovarian response to OS—the POSEIDON
criteria—provide more precise guide in the management of
these women than ESHRE (Bologna) criteria [2]. Although
both existing criteria (Bologna and POSEIDON) use antral
follicle count (AFC) and anti-Mullerian hormone (AMH)
levels as the ovarian reserve tests, many clinicians still com-
monly employ FSH as marker of ovarian reserve in initial
patient assessment prior to IVF cycle initiation [3]. AMH acts
upon both granulosa cells and the oocyte to promote dominant
follicle selection while FSH promotes follicle development
and estradiol production [4, 5] (Fig. 1). Both hormones play
central roles in the orchestration of gonadal function and con-
sequently reproduction. While a multitude of studies have
underlined the superiority of AMH as an ovarian reserve in-
dicator [13–15], the effectiveness of either FSH or AMH as
predictors of IVF outcomes and live birth rate remains ob-
scure. Consequently, the identification of a non-invasive reli-
able predictor of OS success remains a significant goal in
reproductive medicine.
At present, cumulus cell gene expression patterns and as-
sociated products present a promising target for the production
of such a predictor. Folliculogenesis heavily relies upon the
carefully coordinated cross-talk between oocyte associated
cells, such as the cumulus and the oocyte. In the preovulatory
stage (antral follicle), cumulus cells, a specialized type of
granulosa cells, surround the oocyte [16]. Release of the antral
follicle from the prophase I occurs after the LH surge, which
precedes ovulation [17]. Cell cycle release and maturation of
the preovulatory follicle require another process to occur, the
“cumulus expansion,” during which production of hyaluronic
acid and formation of a cumulus-oocyte binding extracellular
matrix takes place [3]. Key mediators of this process are
thought to be a multitude of signaling molecules spanning
from extracellular signaling proteins such as GDF-9 (Growth
Differentiation Factor 9), connexins, and PTX3 (Pentraxin 3),
to transcription factors (FIGα) and catalytic mediators such as
PDE3A (phosphodiesterase 3A) and HAS2 (hyaluronic acid
synthase 2) [18–21]. This process partially triggers the oocyte
maturation and the formation of a mature cumulus-oocyte
complex, which results in an oocyte arrested at the metaphase
of the second meiotic division, ready for ovulation and fertil-
ization [3]. Accumulating evidence from a plethora of studies,
although conducted upon model organisms, suggests that the
orchestration of interaction of the above mediators present key
events in successful folliculogenesis.
To assess the AMH effect upon the intricate interaction
between cumulus cells and oocyte, we analyzed through
transcriptomic approaches the differential expression of cu-
mulus cell genes in younger patient (higher AMH levels,
group A) vs. older (lower AMH levels, group B) groups with
documented variat ions in AMH and FSH levels.
Transcriptomic data were relayed upon the known FSH and
AMH interactomes to underpin the effects of each hormonal
driver upon this interaction. The AMH interactome was found
to be significantly enriched in our differentially expressed
genes with hits such as SMAD family members 1, 4, and 5
(SMAD1, SMAD4, SMAD5), ALK1 (Activin A receptor like
type 1), and LEF1 (Lymphoid Enhancer Binding Factor 1),
which are significant members of the AMH signaling cascade
[4, 6, 7]. We further pursued this biological link in retrospec-
tive, clinical data of 80 patients, to investigate whether AMH
presented a more sensitive indicator of IVF outcomes such as
oocytes retrieved per cycle, oocytes fertilized (day 2, grades A
and B embryos), and number of day 3 embryos. Secondary
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outcomes included positive correlation yet not statistically
significant, of higher AMH levels with live births. This is
the first analysis to combine biological and clinical data, with
a bench-to-bedside approach, in support of AMH superiority
in comparison with FSH as a positive predictor of positive
IVF outcomes in terms of number of oocytes retrieved, grades
A and B, day 2 and day 3 embryos.
Materials and methods
Patient data collection and demographics
RNA-sequencing Raw RNA-sequencing data of cumulus cells
were sourced from younger (n = 10) patient group (group A)
(age 29 (± 1 year of age), baseline FSH 7.4 (± 0.5 mIU/ml),
Fig. 1 AMH and FSH signaling pathways, cellular outcomes, and main
functions in IVF practice. (Blue cell) AMH binds to the Amhr2 receptor,
leading to the formation of the Amhr2-Alk2, 3, and 6 type 1
transmembrane serine/threonine kinase complex. Activated complex ini-
tiates the phosphorylation of Smad proteins 1, 5, and 8. The latter bind to
Smad4 allowing entry into the nucleus leading to follicle selection regu-
lating genes. Smad6 which acts as a negative regulation of both BMP and
TGF-beta/activin-signaling inhibits nuclear translocation of the activated
complex leading to transcriptional suppression of Smad 1, 5, 8 targets. An
accessory pathway through AMH stimulated b-catenin activation and
subsequent binding to LEF-1 (Lymphoid Enhancer Binding Factor 1)
further induces expression of Smad-dependent genes [3, 6, 7]. (Pink cell)
FSH binding to the Fshr G protein-coupled receptor has been shown to
activate the Gαs/cAMP/protein kinase A (PKA) signaling pathway [8].
Appl1 interacts with the FshR to trigger the PI3K signaling pathway
while Src family members promote a similar activation in an FSH-
dependant fashion, while triggering a similar response for the ERK cas-
cade [9, 10]. Coupling of FshR to Gαh (tissue transglutaminase) leads to
PLCδ activation [11]. Downstream effectors of these cascades, namely,
Foxo1, Creb, and c-Jun, become activated through phosphorylation and
translocate to the nucleus, leading to the expression of follicular develop-
ment regulating genes as well as driving the expression of Estradiol. The
FSH signaling cascades have been extensively reviewed in [12]
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AMH 4.67 (± 1.56 ng/ml)) and older (n = 10) patient group
(group B) (age 43 (± 0.5 years of age), baseline FSH 8
(± 0.8 mIU/ml), AMH 1.07 (± 0.44 ng/ml)) [22] (Fig. 2c).
Retrospective clinical analysis We collected, retrospectively,
patient data from 80 infertile patients (with adequate and POR:
poor ovarian reserve) selected according to the inclusion criteria
stated below. All these women were referred to the Institute of
Reproductive Medicine, Lito Hospital of Athens and the
Institute of Life, Iaso Hospital of Athens, between March 2015
and April 2018. Inclusion criteria were as follows: (1) age (28–
48 years of age), (2) two normal semen analyses, according to
the 2010World Health Organization criteria to exclude for male
infertility [23], and (3) normal uterine cavity as well as tubal
patency, which had been established via transvaginal ultrasound
and hysterosalpingography or laparoscopy [24]. Ovarian reserve
in all participants was assessed according to the guidelines of the
American College of Obstetricians and Gynecologists [1].
Anonymized patient data can be found in Sup. Table 1. The
eighty patients that met the inclusion requirements underwent
196 cycles (in total for all patients) of ovarian stimulation under
the human menopausal gonadotropin (hMG, hMG-group) an-
tagonist protocol. Day 2 grades A and B embryos (oocytes
fertilized) and day 3 (grades A and B) embryos were assessed
according to the ASEBIR embryo assessment criteria [25] ac-
cording to morphology (number of cells, fragmentation%, sym-
metry, multinucleation, vacuoles, zona pellucida integrity).
Embryos did not undergo pre-implantation genetic screening.
The study was approved by the ethics committee of the Lito
Maternity Hospital of Athens and the Institute of Life, Iaso
Hospital of Athens. The study was also reported at the clinical
trials registry (clinicalTrials.gov) with registration number
NV24042014.
Treatment schedule
All patients had serum AMH levels measured within a 3-
month period prior to stimulation and serum levels of FSH
and E2. AMH levels were assessed using the ultra-
sensitive AMH/MIS ELISA kit (Ansh Labs), the automat-
ed access AMH assay (Beckman-Coulter), or the Elecsys®
AMH Immunoassay (Roche). Thyroid function of the par-
ticipants as well as serum prolactin was also conducted to
exclude endocrine causes of infertility although not record-
ed in our dataset for analysis. All women were evaluated
on the 2nd day of their menstrual cycle when a transvaginal
ultrasound examination was performed by the same IVF
specialist; serum levels of FSH and estradiol were mea-
sured concurrently. Providing that serum FSH was less
than 16 mIU/ml and estradiol was less than 70 pg/ml, ovar-
ian stimulation was initiated on day 3 with starting dose
150–300 IU of human menopausal gonadotropins (hMG)
(MENOPUR®; Ferring Pharmaceutical Hellas AE)
dependent on the age of the woman, BMI, baseline serum
FSH and E2 levels, and serum AMH levels. All patients
were re-evaluated on day 5 of stimulation (day 8 of the
cycle), when a transvaginal sonogram was performed to
evaluate follicular growth and serum estradiol levels were
measured again. On day 6 of stimulation or when a leading
follicle reached diameter of 14 mm, a commercially avail-
able GnRH antagonist, Cetrorelix acetate 0.25 mg/day, was
initiated (Cetrotide; Merck Serono Hellas AE). Patients
had serial evaluations as needed. When at least two folli-
cles reached an average diameter of 18–20 mm, final oo-
cyte maturation and ovulation was triggered by adminis-
tration of a single dose of recombinant hCG (Ovitrelle®).
Transvaginal ultrasound–guided follicular punctures and
oocyte retrieval were performed 36 h post-hCG adminis-
tration. The standardized ICSI protocol for oocyte manip-
ulation and fertilization optimized from the Fertility Lito
Unit (ISO: 9001:2008) was applied to all oocytes available
for fertilization and one or a maximum of two embryos
were transferred on day 3 after oocyte retrieval. All embryo
transfers were performed by the same specialist under
transabdominal ultrasound guidance to assess the endome-
trial cavity. Embryos were evaluated by the scoring system
established by the Istanbul consensus workshop on embryo
assessment [25]. Micronized progesterone (Utrogestan;
Angelini Pharma ABEE) was used for supplementation of
the luteal phase (200 mg four times daily vaginally) [26].
Serum beta-hCG was measured 12 days after the OPU
(Ovum Pick Up) and clinical pregnancy was confirmed
by ultrasound visualization of foetal heart rate 2 weeks
later.
Outcome measures
The primary outcomes measured were number of oocytes re-
trieved, oocytes fertilized [25], and total day 3 number of
embryos. Secondary outcome was live birth rate. Finally, we
compared primary outcomeswith AMH and FSH level as well
as their genetic pathways (interacting genes) to demonstrate
the predictive accuracy.
Sample size calculation Type I error rate was set at 0.05, type II
error rate (β) = 0.2 as generally accepted standard for clinical
research. Expected correlation coefficient was set at 0.4 for
positive and − 0.4 for negative correlation. The minimum sam-
ple size was calculated as to achieve a p value of < 0.05 and
include the expected correlation coefficient [27]. In this study,
we recruited 80 patients that met our inclusion criteria, leading
to 196 data entries (data entry was considered as a unit).
RNA-sequencing analysis RNA samples were retrieved and
sequenced using the Illumina HiSeq 2000 sequencing plat-
form, as described in the SRA database of NCBI resource with
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study code (GEO Accession: GSM21575/35-44; GEO
Accession: GSM21575/45-55) [22]. Patient allocation into
age groups was conducted as described in [22], where differ-
ence observed among the two groups, e.g., group A (younger)
29 (± 1.0 years) vs group B (older) 43 (± 0.5 years), p value <
0.0001, was statistically significant, considering the limita-
tions in the age groups that can be considered for ART.
Covariate adaptive randomization [28] due to the small sam-
ple size with online randomization (http://www.graphpad.
com/quickcalcs/index.cfm) of the patients assigned in each
age group was employed to generate the 20 participants that
agreed to provide genetic samples for RNA-sequencing in
order to minimize selection bias. Cumulus RNAwas extracted
as described in [22]. Publicly available raw files (FASTA for-
mat) were aligned to Homo sapiens UCSC hg19 reference
genome, trimmed for quality control (QC) analysis, and nor-
malized (Sup. Fig. B) to provide meaningful data. Output data
employed and processed in this study was analyzed succes-
sively in the following order through FLASH (V. 1.2.11.3),
FastQC (v. 10.1), Trimgalore (v. 3.1), Samtools (v. 1.19),
STAR aligner (v. 2.4), and Htseq (v. 5.4) on the Galaxy
Community Platform [29] (usegalaxy.org) was conducted
against the GCA_000001405.28 GRCh38.p13 Homo
sapiens chromosome file provided by the NCBI Genome
Database 21. Raw counts are provided in Sup. Table 2.
Differential gene expression analysis was performed using
Partek® Genomics Suite® software, version 6.6 Copyright
©; 2019. Gene counts (Sup. Table 2) were quantified and
processed through GSA analysis to provide acceptable differ-
ential gene expression data (ratio, fold change, p value of
group A vs. group B comparisons) for 15.601 genes (Sup.
Table 3). Subsequent filtering of dataset for a minimum of 1-
fold of change in expression and a p value of < 0.05 generated
a feature list of 46 differentially expressed genes among all
matched comparisons and processed with hierarchical
Pearson clustering (Sup. Table 3, Fig. 2a). Sample normal
distribution and pipeline of Partek analysis are shown in
Sup. Fig. 1. GO_term analysis was performed in parallel
through the STRING V.11 open platform 2019 [30] and the
Cytoscape v. 2.5.4 Clue GO plugin [31]. Network construc-
tion was performed with Cytoscape V.3.7.2 freeware [32],
Venn diagrams constructed using Venny (v. 2.1.0) online free-
ware [33], and heatmaps with TM4 MultiExperiment Viewer
(MeV) (v. 4.9).
Statistical analysis Statistical analysis was performed using
GraphPad Prism (v. 8). A commercially available statistical
program was used for the statistical analysis. A p value <
0.05 was considered statistically significant. Pearson correla-
tion analysis was performed considering all variables were
continuous (age, FSH/AMH/E2) measurements. All statistical
analysis values (best-fit, slope calculation, 95% CI, Pearson
Correlation r values/p values) are available on Figs. 5 and 7b.
Results
RNA-sequencing data analyzed in this work enabled us to ob-
tain a holistic view of the cellular changes regarding gene ex-
pression, in populations with contrasting AMH and FSH levels.
As data were generated from patients and not obtained from a
controlled, in vitro environment, variation among randomly
matched comparisons (group A vs. group B) was expected.
These variations may have been due to parameters that may
have been recorded such as AMH, FSH, and E2 levels [Fig.
2a–c] or not (patient BMI/medical history, cell culture condi-
tions, heat stress, etc.) affecting cumulus gene expression
[34–36]. Thus, averaging among all groups was employed to
allow for comparison among expressed genes (Fig. 2b).
We further explored the functionality of genes that displayed
strong differential expression (up- or downregulation) with a
bioinformatic approach (Fig. 3). Genes such as PTHLH were
downregulated in the majority of patient comparisons, with a
strongly negative average in the clustering comparison, while
the opposite was true for genes such as TNC (Fig. 2b).
Interestingly, the upregulated cluster of genes significantly
enriched for T cell regulation of cytokine production (IL1R1,
B2M, MTRNR2L8) as well as positive regulation of T cell pro-
liferation (TIMP1, CD24), in support of previous literature
underlining the immunological role of cumulus cells in protec-
tion of the associated oocyte and maintenance of pregnancy [37,
38]. Of note is that while the aforementioned T cell regulation
has been associated with oocyte quality, protection, and preg-
nancy positive outcomes, the particular genes highlighted in this
study have not previously been identified under this association.
Further analysis highlighted upregulated genes (INSIG1,
ATP1A1) that are associated with the negative regulation of
steroid biosynthetic process, mediating regulation of cholesterol
and sterol biosynthesis, thus averting increased steroidogenesis
during early stages of follicular development [39]. On our down-
regulated gene cluster, statistically significant, biological pro-
cesses, such as negative regulation of plasminogen activation
(SERPINE1, THBS1), negative regulation of smooth muscle
migration (IGFBP5), and positive regulation of gap junction
assembly (GJA1, ACE2), were enriched. In murine models, ac-
tive gap junction assembly as well as decreased smooth muscle
migration biological processes have been shown to lead to ovar-
ian failure as well through successful follicular development
blockage [40]. Nonetheless, such association has not yet been
made in human cell linemodels. Yet the present work, highlight-
ing changes in these genetic pathways, should prompt future
in vitro experiments in the field of oocyte development and
maturation.
Pursuing biological hints from the analyzed RNA-
sequencing dataset, we wondered whether known hormonal
markers (such as FSH and AMH) commonly used in clinical
practice to assess ovarian reserve and follicular development
affected gene expression in the examined cumulus cell
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samples. We sourced the FSH and AMH interactome (down-
stream gene targets, associated signaling pathways and
interacting proteins) through the GeneCards, Human Gene
Database [41], and cross-compared hits with our feature gene
list (Fig. 4a). A 1.7% (SMAD1, SMAD4, SMAD5, ALK1,
LEF1) of our target gene list was shared with the AMH inter-
actome, in contrast to a 0.3% (PTHLH) shared with the FSH
interactome. All AMH associated genes were upregulated,
indicating these were expressed in higher levels in younger
patients in comparison to older patients (Fig. 4b). In contrast,
FSH-induced gene, Parathyroid Hormone Like Hormone
(PTHLH), was significantly (p value < 0.0001) lower in group
A compared with group B suggesting that higher FSH levels,
as often observed in older patients, may result in PTHLH
downregulation, potentially underlining the role of calcium
metabolism in anovulatory infertility [42].
To assess AMH as an indicator of oocyte integrity and
embryonal development potential, we collected retrospective-
ly patient data (n = 80) as described in the “Materials and
methods” section. Each IVF trial was noted as a separate event
thus leading to 196 entries originating from 80 patients. The
average number of IVF cycles was calculated at 2.45 (±
1.99 cycles). On stimulation day 2, E2 (35 ± 71.09 ng/l),
FSH (7.91 ± 38.68 mIU/ml), and AMH (1.149 ± 1.26 ng/ml)
levels were measured. AMH (Fig. 5c) displayed a decrease in
concentration in the aging patient population while the oppo-
site was noticeable for FSH (Fig. 5a), a finding in accordance
with previous literature [43]. E2 levels displayed a visible
increase in older patients [44] (Fig. 5b).
We then sought to investigate the correlation between FSH
or AMH levels and oocyte count retrieved and number of
embryos. Data from 73 patients were used, as 7 patients of
our original cohort had opted out for embryo cryopreserva-
tion. Pearson correlation coefficients were calculated for both
outcomes. In regard to oocytes retrieved, the r value of −
0.4179 for FSH indicated a negative, statistically significant
(p value 0.0002) correlation while AMH, a positive, statisti-
cally significant (p value < 0.0001) correlation (r value
0.5993) (Fig. 6a). This result underlined that increased AMH
held a stronger positive correlation with the increased number
of oocytes received for patients undergoing assisted fertiliza-
tion. Furthermore, increased AMH also displayed a stronger,
in terms of significance (p value 0.004), positive correlation (r
value 0.4352) with the number of oocytes successfully fertil-
ized (Fig. 6b). On the other hand, increased levels of FSH
displayed a negative correlation with the final number of day
Fig. 2 Differential expression of genes among randomly matched
younger (n = 10) vs older (n = 10) patients. a Genes displaying over 1
degree of differential expression with statistical significance of < 0.05
were included in the feature list (Sup. Fig. 1). Unfiltered set of differential
gene expression is provided in Sup. Table 3. Feature list genes were
hierarchically clustered and normalized via average linkage, Euclidean
point distance metric as defaults (Sup. Table 4). b Average expression
among all samples for feature list is summarized. each heat map cell
contains the average differential expression among all patient comparison
samples. c Chart depicting sample demographics for significant values
(standard error of the mean) such as AMH, FSH, E2, and age of patients
[22]
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Fig. 4 FSH and AMH interactome within feature, differentially
expressed gene list. a Venn diagram (Venny 2.1.0) highlighting
commonalities between AMH regulated genes vs. FSH regulated genes.
Gene Card Database (https://www.genecards.org) was employed to
identify genetic targets of both FSH (Hit word: Follicle Stimulating
Hormone Subunit Beta. FSHB) and AMH. Target gene lists for each
hormone where compared with the RNA-seq feature (target) list to iden-
tify potential areas of overlap. a One common element was identified
between the “target gene list” and the “FSH interactome”: PTHLH.
Five common elements (representing 1.7% of the target gene list) were
identified between the “target gene list” and the “AMH interactome”
which are as follows: SMAD1, SMAD4, SMAD5, ALK1, LEF1. Lastly,
three common elements were identified between the “AMH interactome”
and the “FSH interactome”: ACVR2A, BMPR1B, SKIL. b Focussed heat
map analysis of Venn diagram sourced, overlapping genes
Fig. 3 Biological analysis with Clue Go Cytoscape plugin of statistically
significant, differentially expressed genes. a Upregulated genes with
associated biological functions as identified through mean and
normalization (Fig. 2b) of each younger vs. older patient comparison
(n = 10) in a network and pie chart representation. b Downregulated
genes with associated biological functions as identified through mean
and normalization of each younger vs. older patient comparison (n =
10) in a network and pie chart representation. Genes that enrich each
category with statistical significance p value < 0.05 appear connected to
each GO_Biological Process node. Thickness of each edge represents
statistical significance. Image was generated and adapted with
Cytoscape plugin Clue GO V.2.5.4 [31]
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E2 (pg/ml) AMH (ng/ml) FSH (mIU/ml)
F (DFn, 
DFd) 0.1564 (1, 140) 2.404 (1, 90) 3.315 (1, 136)
Y Intercept -13.19 2.248 6.093
Slope 1.408 -0.01442 0.107
Y Intercept -79.15 to 52.76 -0.6324 to 5.129 -0.5250 to 12.71






Freedom 140 90 136
R squared 0.02038 0.001808 0.0119
Sum of 
Squares 213645 241.8 2310
Sy.x 39.06 1.639 4.121
Y Intercept 0 0 0
Slope 1.083 0.04058 0.2584




Freedom 141 91 137
R squared 0.01929 -0.02486 -0.01218
Sum of 
Squares 213884 248.3 2366
Sy.x 38.95 1.652 4.156
1630 J Assist Reprod Genet (2020) 37:1623–1635
3 embryos (r value − 0.4027), a result that was not deemed
statistically significant (p value 0.8256). Furthermore, a simi-
lar pattern of correlation was observed between FSH (r value
− 0.22; p value 0.02), AMH (r value 0.59; p value < 0.001),
and the number of day 3 embryos obtained (Table 1). Overall,
these results suggested that while increased FSH held a nega-
tive predictive value for the number of oocytes retrieved, in
our patient group, AMH displayed a statistically stronger as-
sociation with both oocyte retrieval, successful fertilization,
and number day 3 embryos indicating a higher sensitivity as
a marker of positive IVF outcomes.
Furthermore, we pursued to identify putative correlations
between FSH and AMH induction levels and live birth rates
(Fig. 7b). IVF was successful in 54.55% of the patients, ex-
cluding from the total population the women that opted out for
embryo cryopreservation (freeze), 31.82% were unsuccessful
(negative b-hCG test) and 13.64% miscarried (Fig. 7).
Pregnancy outcomes significantly correlated (r value − 0.33,
p value 0.003) with the age of the patient and the initial num-
ber of oocytes received (r value 0.24, p value 0.03) (Fig. 7b)
and while AMH was positively correlated with live birth rate,
the result was not deemed statistically significant in this study
(p value 0.65).
Discussion
In this work we sought to investigate the differences in younger
(age 29) vs. older (age 43) women as stratified in previous work
[22] and consequently differential gene expression in cumulus
cells and assess putative associations with current clinical
markers of oocyte integrity and thus successful IVF outcomes.
Oocyte competence has been long associated with particular
gene differential expression in cumulus cells. Nonetheless, the
majority of these experiments were conducted on bovine sam-
ples, underlining the potential of delicate, species-specific differ-


















































































































Y = 0.2045*X + 1.557
Fig. 6 Simple linear regression and correlation analysis indicating that
increased AMH displays statistically stronger positive correlation with
the number of oocytes received and the final number of oocytes
fertilized. Data of 80 individual patients were analyzed using Pearson
correlation coefficients, computing r value (correlation coefficient) as
well as p value for each correlation and linear regression slopes with
95% confidence bands of the resulting best-fit line. a Linear regression
analysis and Pearson correlation coefficients and statistical significance (p
value) for oocytes retrieved in correlation to FSH and AMH Y intercepts.
b Linear regression analysis and Pearson correlation coefficients and
statistical significance (p value) for oocytes fertilized, FSH and AMH Y
intercepts
Fig. 5 Linear regression lines of E2(pg/ml) (day 2) a, AMH (ng/ml) b,
and FSH (mIU/ml) in relation to age of patient c. In the entirety of our
data entries (n 196 entries; patients 80), FSH (mlU/mL), AMH (ng/ml),
and E2 (pg/ml) day 2 were measured and analyzed with 95% confidence
bands intervals (dotted curves) and non-linear fit lines as shown with
colored edges in each graph. Tabular results of linear regression analysis
shown in a–c
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underlined the importance of particular genes (STAR, COX2,
AREG, GJA1) expressed in human cumulus cells as putative
predictors of oocyte quality and developmental potential
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Fig. 7 Outcomes of ovulation induction (n = 73) and correlation of
variables with pregnancy outcomes. a Pie chart representing outcomes
of ovulation induction including freeze cycles. bTabular representation of
Pearson correlation analysis of live birth (0 unsuccessful, 1 miscarriage, 2
embryo freeze, 3 live birth) with FSH, AMH, patient age, and oocytes
received. Significance is categorized by the NJEM scale, e.g., 0.12 (ns),
0.033 *, 0.002 **, < 0.001 ***














Pearson r − 0.1764 − 0.2266 − 0.1548 0.5939 0.7965 0.8554
95% confidence
interval
− 0.3315 to − 0.01199 − 0.3970 to − 0.04111 − 0.3293 to 0.02999 0.4546 to 0.7048 0.7272 to 0.8497 0.8040 to 0.8941
R-squared 0.03111 0.05135 0.02396 0.3527 0.6344 0.7317
p (two-tailed) 0.04 0.02 0.10 < 0.001 < 0.001 < 0.001
p value summary * * ns *** *** ***
Significant?
(alpha = 0.05)
Yes Yes No Yes Yes Yes
Pearson correlation coefficients were calculated for each pair, with two-tailed p values to assess for statistical significance, Significance is categorized by
the NJEM scale, e.g., 0.12 (ns), 0.033 *, 0.002 **, < 0.001 ***
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Additionally, other studies have underlined the significance of
pentraxin 3 expression as a putative marker of oocyte quality in
humanRNA-seq samples [48]. Nonetheless, grouping of patients
according to age and cross-comparison with oocyte quality as
outcome has not been previously attempted. As human studies
do not allow for direct assessment of oocyte quality, genetic
markers, cumulus cells provide a feasible alternative to infer
oocyte developmental potential.
Here, we highlight the importance of gene expression such as
TNC (Tenascin C), found to be significantly upregulated (3.45-
fold difference) in our younger patient group (Fig. 2a, b). TNC
has been implicated in guidance of migrating neurons, synaptic
plasticity, and regeneration [49]. A previous study has also noted
the increased expression of TNC in cumulus cells and localized
the protein to extracellular matrix and membrane of murine cell
lines [50]. While Tnc has not been deemed essential for the
ovulation process in murine models as tnc−/− mice were found
to be fertile, similar experiments have not been conducted in
human samples [51]. On the other hand, calcium homeostasis
has been shown to play a significant role in fertility while levels
of PTH were noticeably increased in women with anovulatory
infertility [42, 52]. These clinical observations were corroborated
by our dataset asPTHLH expression was found to be significant-
ly repressed in our younger group of patients (Fig. 2a, b).
Interestingly, our biological markers expressionmatched inverse-
ly the increase of FSH levels and simultaneous decrease of AMH
in our patient sample groups (Fig. 2c).
Bioinformatic approaches enabled us to elucidate the biolog-
ical processes that were represented by our differentially
expressed genes. The upregulation of genes, such as TIMP1,
involved in the proliferation of T cells, as well as the CD24
upregulation, modulator of B and T cell activation, underlined a
novel approach by which cumulus cells might promote immune
system modulation and consequent oocyte and embryo integrity
(Fig. 3a). Furthermore, upregulation of INSIG1which modulates
cholesterol metabolism and glucose homeostasis might either
correspond to the necessity to decrease steroidogenesis during
early stage, follicular development [39], or the previously noted
impairment of INSIG1 expression caused by ART manipulation
techniques [53]. Intriguingly, genes (SERPINE1, THBS1, and
IGFBP5), involved in inhibition of plasminogen activation and
smooth muscle migration, were significantly downregulated in
group A, indicating a relative higher expression in group B (Fig.
3b). This finding is supported by previous clinical studies that
have concluded that higher tissue-plasminogen activator (t-PA)
concentrations are observed in sub-fertile female patients [54].
Data from the present analysis underline putative biological
agents that might be at interplay; nonetheless, the exact mecha-
nism of this process remains to be elucidated and presents ground
for further research.
We further pursued putative associations of the biological
gene targets with increased concentrations of currently used clin-
ical markers of fertility, FSH and AMH. As the AMH
interactome was found to be more extensively overlapping with
our feature gene list, we hypothesized that AMHmight present a
better marker of positive IVF outcomes in comparison to FSH.
Our clinical data come in support of previous literature in terms
of AMH superiority in predicting oocytes retrieved with a posi-
tive correlation [14, 55] (Fig. 6a). Nonetheless, our results could
not statistically confirm a strong (p value < 0.05) association of
AMHwith live birth (Fig. 7b), as primarily AMH functions as a
marker of reproductive longevity rather than predictor live birth.
This result may well be due to patient numbers as AMH/live
birth correlation was a secondary outcome of this work and thus
patient samplewas not calculated upon the statistical significance
of this particular correlation. Furthermore, our data first provided
evidence of AMH superiority in regard to number of grades A
and B, day 3 embryos (Fig. 6b).
Of note was that an obvious limitation of this study was the
unmatched patient RNA-seq, samples with the clinical data. A
limitation was to be expected by the structure of this study due to
its retrospective character. Nonetheless, matched RNA patient
samples and extended registered values in terms of patient de-
mographics (e.g., parameters such as TSH, free T4/T3, proges-
terone levels, prolactin, and cortisol [56, 57] could shed new light
in the biological factors between cumulus cells and oocyte qual-
ity factors while decreasing discrepancies due to patient ethnic
origin. Furthermore, AMH assays were conducted in patient se-
lected, private diagnostic centers. Thus, the authors were only
able to collect data of AMH measurements rather than suggest
a specific AMH kits. Consequently, a standardized singular
AMH kit selection and ideally increased numbers of patients
could increase statistical power potentially enabling current,
not-significant associations to emerge as significant, e.g., AMH
levels and live births. Lastly, standardization of the kits used to
measure hormonal levels could increase the power of this study
by decreasing disparities due to kit sensitivity variations.
Conclusions
Besides the obvious benefits in predicting oocyte quality and
embryo developmental potential from AMH levels and cumulus
cell markers in respect to ART efficacy, another point of clinical
interest might be the decreased probability of high-order multiple
gestations. The negative impact of multifetal gestation on both
embryo and mother has been extensively documented [58]. As
efficiency of ARTapproaches increase and double embryo trans-
fer (DET) cycles become a trend due to clinical outcomes and
cost-effectiveness, a drift towards higher order pregnancies has
been observed [59]. Being able to predict embryo developmental
potential and live birth probability would further decrease risks
associated with such pregnancies, such as miscarriage, post-
partum hemorrhage, and mortality, as well as neonatal prematu-
rity, disability, and mortality. Clinical and biological findings of
this study suggest that AMH and its interactome in cumulus cells
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might present such clinical predictive solutions without
compromising oocyte integrity, a statement that remains to be
fully elucidated by aforementioned experimental approaches.
Overall, this study offers new insight on AMH effects upon
cumulus cells and new aspects on how AMH might promote
oocyte integrity and embryo viability at a biochemical level as
well as underline AMH clinical potential as a more sensitive
marker of IVF outcomes than FSH.
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